Sign in

NCT03125720Completed

Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)

Source: ClinicalTrials.gov · Last updated 17 Aug 2025

Brief summary (registry, in English)

CRT response will be significantly better using image fusion of SPECT MPI and fluoroscopy venogram to guide LV lead placement at the latest activation segment without scar than standard-of-care implantation.

Status (registry)
Completed
Study type
Interventional
Enrollment
300 (actual)
First submitted
14 Apr 2017
Start date
14 Apr 2017
Primary completion date
31 Dec 2024
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
NCT number
NCT03125720

What you commit to

  • Study type: Interventional
  • Participants enrolled: 300
  • From 14 Apr 2017 to the primary completion date, 31 Dec 2024
  • 14 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patient is on continuous or intermittent (i.e., more than two infusions per week) intravenous inotropic drug therapy
  • Patient with CRT device implanted previously

Other illness

  • Patient has mechanical right heart valve
  • Patient has experienced unstable angina, acute MI, CABG or PCI within the past 3 months
  • Patient known to have chronic permanent atrial arrhythmias (i.e., cases of long-standing atrial fibrillation of greater than 1 year, including those in which cardioversion has not been indicated or attempted).
  • Patient has had a heart transplant
  • Patient has third degree AVB with normal cardiac function

Age

  • Patient is under a minimum age requirement (\<18 years old)

Other

  • Patient is enrolled in any other study
  • Patient has a life expectancy of less than 12 months
  • Women who are pregnant, or with child-bearing potential and who are not on a form of birth control

Who the study is looking for

  • Patient has signed informed consent
  • moderate to severe HF (NYHA Class II, III or IV)
  • LVEF ≤35%
  • QRS duration ≥130 ms
  • sinus rhythm

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (14)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fu Wai Hospital
Coordinator of this site? Confirm its status
BeijingChinaUnknown status
West China Hospital
Coordinator of this site? Confirm its status
ChengduChinaUnknown status
The First Affiliated Hospital of Dalian Medical University
Coordinator of this site? Confirm its status
DalianChinaUnknown status
Sir Run Run Shaw Hospital
Coordinator of this site? Confirm its status
HangzhouChinaUnknown status
First affiliated hospital, Zhejiang University
Coordinator of this site? Confirm its status
HangzhouChinaUnknown status
First People's Hospital of Hangzhou
Coordinator of this site? Confirm its status
HangzhouChinaUnknown status
Anhui Provincial Hospital
Coordinator of this site? Confirm its status
HefeiChinaUnknown status
Shanghai Chest Hospital
Coordinator of this site? Confirm its status
ShanghaiChinaUnknown status
Zhongshan Hospital
Coordinator of this site? Confirm its status
ShanghaiChinaUnknown status
The General Hospital of Shenyang Military
Coordinator of this site? Confirm its status
ShenyangChinaUnknown status
Xijing hospital
Coordinator of this site? Confirm its status
Xi'anChinaUnknown status
First Affiliated Hospital Xi'an Jiaotong University
Coordinator of this site? Confirm its status
Xi’anChinaUnknown status
The affiliated hospital of xuzhou medical university
Coordinator of this site? Confirm its status
XuzhouChinaUnknown status
Northern Jiangsu Province People's Hospital
Coordinator of this site? Confirm its status
YangzhouChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.